硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Heparan Sulfate Proteoglycan (HSPG) ,etc. by FLIA (Flow Luminescence Immunoassay)
SDC2; HSPG1; SYND2; Fibroglycan; Syndecan 2; Syndecan Proteoglycan 2; Heparan Sulfate Proteoglycan 1,Cell Surface-Associated; Heparan Sulphate Proteoglycan
(注:單次混測多因子不超過8個指標(biāo) )
- 編號LMA565Ra
 - 物種Rattus norvegicus (Rat,大鼠)相同的名稱,不同的物種。
 - 實驗方法雙抗夾心
 - 反應(yīng)時長3.5h
 - 檢測范圍1.95-2000pg/mL
 - 靈敏度最小可檢測劑量小于等于0.65 pg/mL.
 - 樣本類型Serum, plasma, tissue homogenates and other biological fluids
 - 下載英文說明書 中文說明書
 - 規(guī)格8指標(biāo)數(shù)7指標(biāo)數(shù)6指標(biāo)數(shù)5指標(biāo)數(shù)4指標(biāo)數(shù)3指標(biāo)數(shù)2指標(biāo)數(shù)1指標(biāo)數(shù)
 - 價格¥ 2702¥ 2806¥ 2962¥ 3170¥ 3377¥ 3689¥ 4157¥ 5196 添加到價格計算器 計算器
 - 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
 
特異性
                        本試劑盒用于檢測硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
                        由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
                    
回收率
分別于定值血清及血漿樣本中加入一定量的硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測定并計算其均值,回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) | 
| serum(n=5) | 80-103 | 81 | 
| EDTA plasma(n=5) | 92-101 | 97 | 
| heparin plasma(n=5) | 91-99 | 95 | 
| sodium citrate plasma(n=5) | 98-105 | 102 | 
精密度
                    精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100 
                    批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次,分別計算不同濃度樣本的平均值及SD值。
                    批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定,每個樣本使用同一試劑盒重復(fù)測定8次,分別計算不同濃度樣本的平均值及SD值。
                    批內(nèi)差: CV<10% 
                    批間差: CV<12% 
線性
在定值血清及血漿樣本內(nèi)加入適量的硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 | 
| serum(n=5) | 87-94% | 82-104% | 96-105% | 86-102% | 
| EDTA plasma(n=5) | 81-94% | 98-105% | 78-98% | 93-105% | 
| heparin plasma(n=5) | 83-101% | 91-98% | 81-101% | 89-97% | 
| sodium citrate plasma(n=5) | 94-101% | 97-105% | 99-105% | 82-90% | 
穩(wěn)定性
                    經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
                    為減小外部因素對試劑盒破壞前后檢測值的影響,實驗室的環(huán)境條件需盡量保持一致,尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進(jìn)行操作可減少人為誤差。
                
實驗流程
1. 實驗前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
                            2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
                                37°C酶標(biāo)板振蕩器孵育90分鐘;
                            3. 磁吸甩干,加檢測溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
                            4. 磁吸洗板3次;
                            5. 加檢測溶液B100μL,37°C振動孵育30分鐘;
                            6. 磁吸洗板3次;
                            7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) | 
| RPA565Ra01 | 硫酸肝素蛋白聚糖(HSPG)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| PAA565Ra01 | 硫酸肝素蛋白聚糖(HSPG)多克隆抗體 | WB; IHC; ICC; IP. | 
| SEA565Ra | 硫酸肝素蛋白聚糖(HSPG)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. | 
| LMA565Ra | 硫酸肝素蛋白聚糖(HSPG)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. | 
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) | 
| Journal of Applied Pharmaceutical Science | Cytotoxic effects of antiglypican-3 against HepG3 cell line[Ebscohost: Source] | 
| Journal of Reproductive Immunology | Fibrinogen, an endogenous ligand of Toll-like receptor 4, activates monocytes in pre-eclamptic patients[Pubmed: 24661950] | 
| European journal of pharmacology | Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme[Pubmed: 24530413] | 
| European Journal of Pharmacology | Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma[Pubmed:25449037] | 
| Shock | Impairment of the Endothelial Glycocalyx in Cardiogenic Shock and its Prognostic Relevance[Pubmed:25692257] | 
| Biomarkers in Medicine | Endothelial glycocalyx layer shedding following lung resection[pubmed:27643669] | 
| Apmis | Circulating syndecans during critical illness.[pubmed:28256016] | 
| Biomedicine & Pharmacotherapy | Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 and[Pubmed:29669302] | 
| Drug?Delivery | Glioma targeting peptide modified apoferritin nanocage[Pubmed:29726297] | 
| Anaesthesia | Postoperative microcirculatory perfusion and endothelial glycocalyx shedding following cardiac surgery with cardiopulmonary bypass[Pubmed: 30687934] | 
| Animals | Diet Supplementation with a Bioactive Pomace Extract from Olea europaea Partially Mitigates Negative Effects on Gut Health Arising from a Short-Term Fasting Period …[] | 
| LIFE SCIENCES | Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients[33781826] | 
| Genet Mol Biol | A novel mutation in ext2 caused hereditary multiple exostoses through reducing the synthesis of heparan sulfate[34042151] | 
| Poultry Science | Response of broiler chickens fed diets supplemented with a bioactive olive pomace extract from Olea europaea to an experimental coccidial vaccine??-[33518110] | 
| J Gerontol A Biol Sci Med Sci | The effect of pre-operative methylprednisolone on postoperative delirium in elderly patients undergoing gastrointestinal surgery: a randomized, double-blind, placebo?…[34423832] | 


